The <i>FGFR3</i> Mutation is Related to Favorable pT1 Bladder CancerBas W.G. van Rhijn, Bharati Bapat, Theodorus van der Kwast et al.|The Journal of Urology|2011Cited by 102
FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?†Bas W.G. van Rhijn, Tahlita C.M. Zuiverloon, Laura S. Mertens et al.|European Urology|2020Cited by 89
Prognostic value of molecular markers, sub‐stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancerBas W.G. van Rhijn, Alexandre R. Zlotta, Liyang Liu et al.|British Journal of Urology|2012Cited by 64
Molecular and clinical support for a four-tiered grading system for bladder cancer based on the WHO 1973 and 2004 classificationsBas W.G. van Rhijn, Theodorus van der Kwast, Mireía Musquera et al.|Modern Pathology|2014Cited by 47
Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patientsLaura S. Mertens, Bas W.G. van Rhijn, Francesco Claps et al.|Urologic Oncology Seminars and Original Investigations|2021Cited by 39